Genmab — September 2017
-
Jeg kiggede lige lidt igen på ADCT-301 i refractory Hodgkin’s and non-Hodgkin’s lymphoma. Ret imponerende tidlige interim data.. Uden at have nået MTD har de allerede tre CR. http://adctherapeutics.com/downloads/1497568261.pdf. Og Genmab ejer som bekendt fortsat 25%.En mulig trigger hen ad vejen. Når vi nu er ved den slags...
-
I am not sure if we posted this here last week, Tecentriq study to be placed on partial clinical hold, NCT02431208 is a Dara combo https://myelomaresearchnews.com/2017/09/20/safety-concerns-lead-to-partial-hold-on-2-tecentriq-trials-in-myeloma-and-lymphoma/
-
-
Ved ikke om dette nye studie er nævnt: https://clinicaltrials.gov/ct2/show/NCT03289299?term=NCT03289299&rank=1
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind